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Foreword
CDC is proud by means of this publication to make available in one place all the
recommendations of the International Task Force for Disease Eradication. My immedi-
ate predecessor as Director of CDC, Dr. William Roper, CDC’s Deputy Director Dr.
Walter Dowdle, and many other CDC professional staff participated in the delibera-
tions of the Task Force. In addition, this project illustrates the close collaboration
between CDC and our colleagues at The Carter Center of Emory University.
This systematic review of diseases as possible candidates for eradication is an im-
portant follow-up to the successful eradication of smallpox in 1977, a campaign that
ranks among the finest achievements of CDC, in conjunction with other organizations.
The World Health Organization has now targeted two other diseases for eradication.
Dracunculiasis (Guinea worm disease) is scheduled to be eradicated by the end of
1995 and poliomyelitis by the end of the year 2000. The substantial progress already
evident toward achieving these two goals confirms the wisdom of the Charles A. Dana
Foundation in making a grant in 1988 to establish the secretariat of this Task Force. In
addition to endorsing the two targets of dracunculiasis and poliomyelitis eradication,
the Task Force has helped to chart logical next steps for humankind’s use of the pow-
erful weapon of eradication. It has done this by identifying four other diseases as
potential long-term targets for eradication—rubella, mumps, cysticercosis, and filari-
asis—and by establishing clear criteria that can be used in an ongoing process of
evaluation of candidate diseases and conditions in the light of new discoveries.
As the world gains more confidence with successful disease eradication cam-
paigns, I hope we shall have the courage and foresight to embrace other appropriate
targets for eradication and work diligently to achieve them.
David Satcher, M.D., Ph.D.                     
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Recommendations of the International Task Force
for Disease Eradication
Summary
This report summarizes the conclusions of the International Task Force for
Disease Eradication (ITFDE), a group of scientists who were convened by a sec-
retariat at the Carter Center of Emory University six times during 1989–1992. The
purpose of the ITFDE was to establish criteria and apply them systematically to
evaluate the potential eradicability of other diseases in the aftermath of the
Smallpox Eradication Program. The ITFDE defined eradication as “reduction of
the worldwide incidence of a disease to zero as a result of deliberate efforts,
obviating the necessity for further control measures.”
The names of the members of the ITFDE, the criteria they developed and
used, and summaries of the papers that were presented to the ITFDE by various
experts are included in this report, as well as a brief history of the concept of
disease eradication since the late 19th century. The ITFDE considered more than
90 diseases and reviewed 30 of these in depth, including one noninfectious dis-
ease. It concluded that six diseases—dracunculiasis, poliomyelitis, mumps,
rubella, lymphatic filariasis, and cysticercosis—could probably be eradicated by
using current technology. It also concluded that manifestations of seven other
diseases could be “eliminated,” and it noted critical research needs that, if real-
ized, might permit other diseases to be eradicated eventually. The successful
eradication of smallpox in 1977 and the ongoing campaigns to eradicate dracun-
culiasis by 1995 and poliomyelitis by 2000 should ensure that eradication of
selected diseases will continue to be used as a powerful tool of international
public health.
INTRODUCTION
This issue of MMWR Recommendations and Reports consolidates the delibera-
tions of the International Task Force for Disease Eradication (ITFDE), which was
convened six times from 1989 through 1992 to evaluate diseases as potential candi-
dates for global eradication (1–7 ). CDC supports the findings in this report, which
indicate a need for greater recognition of the potential to eradicate targeted diseases.
Three reports, covering results of the first five meetings, were published previously in
the MMWR (1–3 ), and reprinted in WHO’s Weekly Epidemiological Record (4–6 ). A
report of the sixth meeting was also published in the Weekly Epidemiological Record
(7 ).
Eradication is defined as reduction of the worldwide incidence of a disease to zero
as a result of deliberate efforts, obviating the necessity for further control measures.
The criteria that the ITFDE developed and their conclusions after reviewing more than
90 diseases are presented in this report.
An important part of the work was to help identify key impediments to improved
prevention and control of the diseases under discussion, even if the disease was not
considered to have potential as a candidate for eradication. One such “noneradication
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outcome” was the impetus that the members of the ITFDE gave to initiating a demon-
stration project to control intestinal parasites among schoolchildren in Ghana.
A SPECTRUM OF DISEASE CONTROL
Between the extremes of disease “control” (reduction in incidence and/or preva-
lence) and “eradication,” several intermediate levels of impact on diseases may be
described. The term “elimination” is sometimes used synonymously with “eradica-
tion,” but it refers to a single country, continent, or other limited geographic area,
rather than global eradication. True eradication usually entails eliminating the micro-
organism itself or removing it completely from nature, as in the case of smallpox
virus, which now exists only in storage in two laboratories. It is also theoretically pos-
sible to “eliminate” a disease in humans while the microbe remains at large, as in the
case of neonatal tetanus, for which the World Health Organization (WHO) in 1989 de-
clared a goal of global elimination by 1995.
Although a disease itself may remain, a particularly undesirable clinical manifesta-
tion of it may be prevented entirely. Examples of this level of eradication are the use
of chemotherapy with ivermectin to eliminate blindness resulting from onchocerciasis
and of vitamin A to eliminate xerophthalmia. Eliminating transmission of a disease
may also be considered, as in the case of yaws, the late noninfectious clinical manifes-
tations remain of which but are not a danger to others. Finally, “elimination” can be
defined as control of the manifestations of a disease so that the disease is no longer
considered “a public health problem,” as an arbitrarily defined qualitative or quantita-
tive level of disease control (e.g., WHO’s goal of eliminating leprosy by the year 2000,
which is defined as reducing its incidence to a level below one case per 10,000 popu-
lation).
Even as smallpox was being eradicated, public health authorities recognized that
the eradication campaign was possible because of several important characteristics of
smallpox and the smallpox vaccine. Smallpox was epidemiologically vulnerable be-
cause it had no natural reservoir in species other than humans; the infection was
obvious and usually easily diagnosed; the duration and intensity of infectiousness
were limited; persons who recovered were immune for life and often permanently
scarred; and its transmission was highly seasonal in many areas. The vaccine was
safe, effective even in newborns, inexpensive, easily administered, and stable in tropi-
cal climates; its effects were long-lasting; and vaccinated persons had a recognizable
scar (8 ).
As a tool for international public health, eradication of well-chosen diseases has
two advantages:
• Eradication is permanent, as are its benefits. In contrast, the costs of control pro-
grams continue indefinitely, along with the risks of future exacerbation of the
disease following a disaster of natural or human origin. For some diseases,
achieving control would require only marginally less effort than that needed to
achieve eradication, but control measures would need to be continued indefi-
nitely. Eradication is the ultimate “sustainable” improvement in public health.
The recent reimportation of wild poliovirus into the Western Hemisphere more
than 18 months since its last known previous occurrence (9 ) and the possibility
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of changes in other pathogens in ways that can make them impervious to once-
effective control measures (10 ) would not be of concern had successful
eradication campaigns taken place. (Fear of the consequences of emerging resis-
tance of malarial mosquito vectors and of the parasite itself was partly
responsible for the precipitous decision in the 1950s to eradicate malaria.)
• A time-limited goal of eradication allows mobilization of support for a concen-
trated effort more readily than does a control program—both within countries
where the disease is endemic and internationally. If developed countries have to
spend resources to prevent or control importations of the disease (e.g., polio-
myelitis, smallpox), such countries have additional incentive to help support an
eradication campaign.
Participation in a successful eradication campaign can also be effective in improv-
ing the morale and performance of workers in public health, although this potential
benefit can also be derived from a control program. An eradication campaign requires
complete surveillance, rigorous administration, and operational research to a degree
that may not be necessary in a control program because the standard of success in an
eradication program is unambiguous and uncompromising. Another requirement of
an eradication campaign may be funding to support measures to eliminate a minor
focus of disease from a country where the disease has limited impact and does not
constitute a national priority.
The potential negative effects of an eradication campaign, especially an unsuccess-
ful one, must also be weighed. One study stressed the economic consequences and
the potential negative impact on broader public health programs (11 ). The possible
effects of competition for scarce resources and the political implications are among
the factors that should be considered (12 ).
The ITFDE developed specific criteria to consider the potential for eradication of
diseases other than smallpox (Table 1). These criteria acknowledge that combinations
of favorable characteristics other than those that obtained for smallpox might permit
other diseases to be eradicated. They generally include elements similar to previously
suggested criteria (11,12 ); however, the criteria of the ITFDE distinguish scientific fea-
sibility from sociopolitical feasibility.
A BRIEF HISTORY OF DISEASE ERADICATION
Every friend of humanity must look with pleasure on this discovery [smallpox vaccina-
tion], by which one evil more is withdrawn from the condition of man; and must
contemplate the possibility that future improvements and discoveries may still more
and more lessen the catalogue of evils. 
— Thomas Jefferson, 1800
The eventual eradication of smallpox as a result of the use of Jennerian vaccination
was predicted by Edward Jenner, as well as by Thomas Jefferson, in the early 19th
century. Following the emergence of the germ theory and more systematic ap-
proaches to disease control in the mid-19th century, the concept of eradication of a
disease first became popular briefly around the turn of the century. Milestones in the
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history of disease eradication over the years have been summarized (Table 2). Conta-
gious pleuropneumonia of cattle, a disease that had been imported into the United
States in 1843, was declared eradicated from the country in 1892, following a 5-year,
$2-million campaign to identify and slaughter infected animals (13 ).
The Rockefeller Foundation began campaigns to eradicate hookworm in 1907 and
yellow fever in 1915. Both these campaigns against diseases of humans failed: the
hookworm campaign because mass treatment of affected populations with an-
thelmintic therapy reduced the severity of individual infections but rarely eliminated
them and thus did not prevent rapid reinfection (14 ); and the campaign against yellow
fever because of the previously unknown, inaccessible cycle of disease among nonhu-
man primates living in forests (15 ). Acceptance of the concept of eradication declined
during the late 1920s and early 1930s, after the futility of the eradication of hookworm
and yellow fever was recognized.
The concept became popular again in the late 1940s, following the elimination of
Anopheles gambiae mosquitoes from Brazil and Egypt, the elimination of malaria
from Sardinia, reductions in the prevalence of yaws in Haiti, and the introduction of a
stable freeze-dried vaccine against smallpox (13,15 ). By 1955, WHO had declared
goals of global eradication of yaws and malaria, and in 1958 it adopted the goal of
smallpox eradication as well. The yaws campaign failed, partly because persons with
inapparent latent cases were not adequately treated, in addition to persons with clini-
cal disease. Many such latent infections relapsed to produce infectious lesions soon
Scientific Feasibility
• Epidemiologic vulnerability (e.g., existence of nonhuman reservoir; ease of
spread; natural cyclical decline in prevalence; naturally induced immunity;
ease of diagnosis; and duration of any relapse potential)
• Effective, practical intervention available (e.g., vaccine or other primary pre-
ventive, curative treatment, and means of eliminating vector). Ideally,
intervention should be effective, safe, inexpensive, long-lasting, and easily de-
ployed.
• Demonstrated feasibility of elimination (e.g., documented elimination from
island or other geographic unit)
Political Will/Popular Support
• Perceived burden of the disease (e.g., extent, deaths, other effects; true bur-
den may not be perceived; the reverse of benefits expected to accrue from
eradication; relevance to rich and poor countries).
• Expected cost of eradication (especially in relation to perceived burden from
the disease).
• Synergy of eradication efforts with other interventions (e.g., potential for
added benefits or savings or spin-off effects)
• Necessity for eradication rather than control
TABLE 1. Criteria for assessing eradicability of diseases and conditions
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after mass treatment teams visited a community. Later, disease-specific control meas-
ures were withdrawn prematurely, allowing the infection to reappear in several areas
(16 ).
Failure to achieve malaria eradication, after an expenditure estimated at $1.4 billion
during the period 1955–1965, brought the concept of eradication into disfavor again
(17 ). Resistance of some vectors to insecticides and of some parasites to treatment,
the unexpected diversity and tenacity of some vectors, administrative shortcomings,
and rising costs were all factors in the decision to abandon the goal of eradicating
malaria (18 ). (WHO officially revised the goal to one of control in 1969.) The achieve-
ment of global smallpox eradication in 1977 and its official certification by WHO in
1980 did not at first bring about the acceptance of the concept of eradication. Con-
cerns were raised that a new eradication effort might detract from efforts to focus
attention on the need for developing comprehensive primary health services, rather
than focusing on one or two diseases (19 ). However, several diseases (e.g., schis-
tosomiasis, rotavirus diarrhea, brucellosis, and leprosy) that were then being
considered as possible targets for global eradication did not have potential for success
given the current technology. Several reports and conferences have considered the
potential for eradicating other diseases, of which poliomyelitis, mumps, and rubella
were among those most frequently cited (18,20–23 ). Reports in 1980 and 1985 both
concluded that no other major disease was then a potential candidate to be targeted
by a global eradication campaign (18,20 ).
After the concept of eradication was accepted again in the late 1980s, some ob-
servers considered a disease to be unsuitable for eradication to the extent that it
differed from smallpox or that the intervention against it differed from smallpox vac-
cine (24 ). In this third period of acceptance, WHO has targeted dracunculiasis and
poliomyelitis for eradication.
SUMMARY OF THE ITFDE DELIBERATIONS
Ninety-four infectious diseases were screened by the ITFDE (Appendix 1). The IT-
FDE considered 29 infectious diseases in depth, as well as one noninfectious condition
(iodine deficiency). The latter condition was chosen in part to enable the ITFDE to ap-
ply the criteria it had developed to at least one noninfectious candidate for eradication,
as an example in principle. Some infectious diseases that were already proposed for
eradication by WHO or by other organizations or countries were considered by the
ITFDE before the list was completed. Those diseases were not included in the list of
diseases subjected to preliminary screening by the ITFDE.
Of the ninety-four diseases that were screened, the ITFDE concluded that six were
potentially eradicable: dracunculiasis (Guinea worm disease), poliomyelitis, mumps,
rubella, lymphatic filariasis, and taeniasis/cysticercosis (pork tapeworm). Of these,
only the first two had already been targeted for global eradication. The ITFDE also
noted that seven other conditions or clinical manifestations of diseases might be
eliminated: blindness from onchocerciasis, urban rabies, transmission of yaws and
other endemic treponematoses, transmission of hepatitis B, transmission of neonatal
tetanus, blindness from trachoma, and iodine deficiency disorders. Key obstacles to
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1888 Charles V. Chapin urges eradication of tuberculosis (TB).
1892 Contagious pleuropneumonia of cattle declared eradicated  from
United States after 5-year campaign costing $5 million, begun in
1884.
1896 Rabies eradicated from England.
1901 Gen. William C. Gorgas eradicates yellow fever from Havana.
1907 Rockefeller Foundation establishes Sanitary Commission for
Eradication of Hookworm Disease in the United States; eventually
stimulates projects in 52 countries.
1915 Rockefeller Foundation establishes Yellow Fever Commission to
eradicate that disease, under leadership of Gorgas. Fear of im-
porting yellow fever to Asia via Panama Canal.
1917 Decision to eradicate bovine TB from United States.
1922 Rockefeller Foundation’s hookworm campaign begins phasing
out after evaluation shows little impact on transmission.
1923 Yellow fever reappears in Brazil after nearly a year’s absence.
1928–1929 Other outbreaks of yellow fever in Brazil, including in Rio de
Janeiro.
1930 Anopheles gambiae mosquito discovered in Brazil.
1933 Yellow fever realized to be widespread in South American forests;
search for hidden breeding sites of A. aegypti vector reveals its
disappearance from cities of coastal Brazil.
1934 Eradication of A. aegypti in Brazil is proposed.
1937 Wade Hampton Frost reports human TB is being eradicated in the
United States and other countries.
1937–1938 Large fatal malaria epidemics associated with A. gambiae in
Brazil.
1939–1941 A. gambiae eradicated from Brazil.
1943 Bolivia is first country to proclaim eradication of A. aegypti.
1943–1945 A. gambiae eradicated from Egypt.
1947 Pan American Health Organization (PAHO) adopts proposal for
eradication of A. aegypti from Americas.
1950 Pan American Sanitary Conference approves goal of continental
smallpox eradication and continental yaws eradication; begins
collaboration with national malaria eradication programs.
1951 Malaria eradicated from Sardinia.
1954 Yaws eradication goal declared by World Health Organization
(WHO).
1955 Eighth World Health Assembly (WHA) adopts goal of global ma-
laria eradication.
1958 11th WHA adopts goal of global smallpox eradication.
1966 19th WHA adopts goal of intensified global smallpox eradication
by 1976.
TABLE 2. Milestones in disease eradication
6 MMWR December 31, 1993
eradication, elimination, or improved control were also highlighted by the ITFDE in its
discussions of the 30 diseases that it considered in depth (Table 3).
Summaries* of the 30 background papers that were presented to the ITFDE appear
below. At least two of the papers prepared for meetings of the ITFDE have been pub-
lished or accepted for publication (25,26 ).
Diseases Targeted for Eradication
Dracunculiasis (Guinea Worm Disease)
Dracunculus medinensis now affects as many as 2 million persons in India, Paki-
stan, and approximately 16 African countries, where >100 million persons are at risk
for the disease (27 ). Persons are infected by drinking water containing immature
forms of the parasite. A year later, the female adult worms, each about 1 meter long,
emerge through the skin, causing crippling pain that prevents these persons from car-
1969 WHO officially changes malaria eradication policy back to malaria
control, after expenditure of estimated $1.4 billion during 1955–
1965.
1970 Smallpox is eradicated from the Americas.
1975 Europe free of malaria for first time in history.
1977 Smallpox eradicated worldwide.
1978 U.S. goal of measles elimination by 1982 is announced.
1980 Smallpox eradication declared by WHO; International Conference
on Eradication of Infectious Diseases held in Washington; India
begins national dracunculiasis eradication program.
1985 PAHO sets goal of poliomyelitis elimination from Americas by
1990; Europe sets goal of measles elimination by 2000.
1986 39th WHA declares goal of dracunculiasis elimination.
1988 41st WHA declares goal of global poliomyelitis eradication by
2000; African Region of WHO sets goal of dracunculiasis elimina-
tion from Africa by 1995.
1989 International Task Force for Disease Eradication meets for first
time.
1990 WHO meeting on criteria and procedures for certification of
dracunculiasis elimination; PAHO’s Executive Committee begins
considering other potential candidates for elimination in the
Americas by 2000.
1991 44th WHA declares goal of global dracunculiasis eradication by
1995; last case of indigenous poliomyelitis in the Americas occurs
in Peru.
TABLE 2. Milestones in disease eradication, cont’d.
*The summaries were prepared by the project director, based on the working papers presented
to the Task Force. The original authors have not reviewed these summaries. Incidence data
for several diseases have been updated. A single reference is provided for each summary as
a suggestion for further reading.
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TABLE 3. Diseases considered as candidates for global eradication by the International
Task Force for Disease Eradication
Disease
Current annual toll
worldwide Chief obstacles to eradication Conclusion
Diseases targeted for eradication
Dracunculiasis
(Guinea worm
disease)
<2 million persons
infected; few deaths
Lack of public and political
awareness; inadequate
funding
Eradicable
Poliomyelitis 100,000 cases of
paralytic disease;
10,000 deaths
No insurmountable technical
obstacles; increased
national/international
commitment needed
Eradicable
Lymphatic
filariasis
80 million cases Need better tools for
monitoring infection
Potentially eradicable
Mumps Unknown Lack of data on impact in
developing countries;
difficult diagnosis
Potentially eradicable
Rubella Unknown Lack of data on impact in
developing countries;
difficult diagnosis
Potentially eradicable
Taeniasis/
cysticercosis
(pork tapeworm)
50 million cases;
50,000 deaths
Need simpler diagnostics for
humans and pigs
Potentially eradicable
Diseases/conditions of which some aspect could be eliminated
Hepatitis B 250,000 deaths Carrier state, infections in
utero not preventable; need
routine infant vaccination
Not now eradicable,
but could eliminate
transmission over
several decades
Iodine deficiency
disorders
Unknown Inadequate surveillance, lack
of environmental sources of
iodine
Could eliminate
iodine deficiency
disorders
Neonatal tetanus 560,000 deaths Inexhaustible environmental
reservoir
Not now eradicable,
but could prevent
transmission
Onchocerciasis
(river blindness)
18 million cases;
340,000 blind
High cost of vector control;
no therapy to kill adult
worms; restrictions in mass
use of ivermectin
Could eliminate
associated blindness
Rabies 52,000 deaths No effective way to deliver
vaccine to wild animals that
carry the disease
Could eliminate urban
rabies
Trachoma 500 million cases;
6–8 million blind
Linked to poverty; ubiquitous
microbe
Could eliminate
blindness
Yaws and other
endemic
treponematoses
2.5 million cases Political and financial inertia Could interrupt
transmission*
*Because persons may be infected for decades and the organisms cannot be distinguished
from those that cause venereal syphilis, elimination of transmission—not eradication—is the
goal.
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TABLE 3. Diseases considered as candidates for global eradication by the International
Task Force for Disease Eradication
Disease
Current annual toll
worldwide Chief obstacles to eradication Conclusion
Diseases that are not eradicable now
Ascariasis
(roundworm)
1 billion infected;
20,000 deaths
Eggs viable in soil for years;
laborious diagnosis;
widespread
Not now eradicable
Cholera Unknown Environmental reservoirs;
strain differences
Not now eradicable
Diphtheria Unknown Difficult diagnosis;
multiple-dose vaccine
Not now eradicable
Hookworm
disease
900 million
infected; 60,000
deaths
Laborious diagnosis; adult
worms may live 5 years;
widespread
Not now eradicable
Leprosy
(Hansen’s
disease)
11–12 million cases Need for improved
diagnostic tests and
chemotherapy; social stigma;
potential reservoir in
armadillos
Not now eradicable
Measles Almost 1 million
deaths, mostly
among children
Lack of suitably effective
vaccine for young infants;
cost; public misconception of
seriousness
Not now eradicable
Pertussis
(whooping
cough)
40 million cases;
400,000 deaths
High infectiousness; early
infections; multiple-dose
vaccine
Not now eradicable
Rotaviral enteritis 80 million cases;
870,000 deaths
Inadequate vaccine Not now eradicable
Schistosomiasis
(bilharziasis)
200 million infected Reservoir hosts; increased
snail-breeding sites
Not now eradicable
Tuberculosis 8–10 million new
cases; 2–3 million
deaths
Need for improved
diagnostic tests,
chemotherapy and vaccine;
wider application of current
therapy
Not now eradicable
Yellow fever >10,000 deaths Sylvatic reservoir; heat-labile
vaccine
Not now eradicable
Diseases that are not eradicable
Amebiasis 500 million cases;
40,000–110,000
deaths
Asymptomatic infections;
difficult diagnosis, treatment
Not eradicable
Bartonellosis Unknown Asymptomatic infections;
difficult diagnosis, treatment
Not eradicable
Clonorchiasis 20 million cases in
China alone
Animal reservoir;
asymptomatic infections;
carrier state
Not eradicable
Enterobiasis Unknown Widespread; mild disease Not eradicable
American
trypanosomiasis
(Chagas’ disease)
15–20 million
infected
Difficult diagnosis,
treatment; animal reservoirs
Not eradicable
Varicella zoster 3 million cases in
USA alone
Latency of virus; inadequate
vaccine
Not eradicable
, cont’d.
Vol. 42 / No. RR-16 MMWR 9
rying out their daily activities for periods of weeks or months. When infected persons
wade or bathe, the immature forms of the worms enter the water to continue the cy-
cle. Most infections, which induce no immunity and may affect over half a village’s
population during planting or harvest seasons, are not fatal, but secondary bacterial
infections may be life threatening.
Dracunculiasis can be prevented by teaching residents of areas where the disease
is endemic to prevent affected persons from entering drinking water sources and to
boil or filter their drinking water; by providing water from safe sources such as wells;
or by using a chemical to kill the water fleas that harbor the larval parasite. The global
eradication campaign began with the International Drinking Water Supply and Sanita-
tion Decade (1981–1990). In 1986, the World Health Assembly (WHA) adopted the goal
of eliminating dracunculiasis. The goal of eradicating dracunculiasis by 1995 was de-
clared by the WHA in 1991. No technical barriers remain, but more social mobilization
and funding are needed.
Poliomyelitis
WHO estimates that about 100,000 cases of paralytic poliomyelitis still occur annu-
ally worldwide, mostly in Asia and Africa, with approximately 10,000 deaths (28 ). For
every paralytic case, 100 asymptomatic persons carry the virus and can infect others.
This virus is transmitted mostly by airborne droplets from infected persons. Persons
who recover are immune. The incidence of poliomyelitis has been reduced as a result
of the increases in vaccination rates during the drive to vaccinate at least 80% of the
world’s infants by December 1990. (About 85% were vaccinated against poliomyelitis.)
Protection against poliomyelitis requires three or four injections or oral doses of vac-
cine.
In 1985, the Pan American Health Organization declared the goal of eliminating po-
liomyelitis from the Americas by 1990—a goal that apparently has been achieved,
with the final cases reported from Peru in September 1991. In 1988, the WHA declared
the goal of eradicating poliomyelitis from the world by the year 2000. WHO now esti-
mates that the external costs of eradicating poliomyelitis will be about U.S. $1.1
billion. Poliomyelitis eradication appears to be technically feasible and would be facili-
tated by development of a vaccine that requires fewer doses or is more heat stable.
The most urgent need is for adequate supplies of the existing vaccine and additional
funding.
Diseases that Could Potentially Be Eradicated
Lymphatic Filariasis
Lymphatic filariasis is caused by any of three species of parasitic worms: Wucher-
eria bancrofti, Brugia malayi, or Brugia timori (29 ). Nearly 80 million persons are
infected in the tropics and subtropics after long exposure to the bites of certain mos-
quitoes. Adult worms can live in the lymphatic system for 10–15 years. Female worms
discharge microfilariae into the blood, where they can infect other mosquitoes and
through them, other humans. Humans are the only reservoir of infection, except for B.
malayi, which has a reservoir in nonhuman primates that does not appear to contrib-
ute to transmission to humans. Complications include swellings of limbs or other
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appendages (elephantiasis) from interaction of the parasite with the host’s immune
system. Many infected persons have no symptoms, and the infection is not fatal.
The impact of this infection and disease has been reduced in several areas by mass
treatment of populations with diethylcarbamazine (DEC). DEC also has some adulti-
cide effect. Ivermectin is another effective drug that is inexpensive and easily
administered. Some side effects may occur after either drug, which may be adminis-
tered once a year. Improved tests are needed for detecting and monitoring infection.
More data are needed about costs of intervention and the effects of ivermectin mass
treatment of onchocerciasis on filariasis in West Africa. This disease may be eradica-
ble by using single doses of invermectin, DEC, and salt containing DEC.
Mumps
Mumps is a viral disease that occurs worldwide and usually affects children (30 ). It
is characterized by fever and painful swelling of the parotid salivary glands. Complica-
tions may include orchitis, meningitis, and encephalitis, but inapparent infections are
common. Spread by direct contact and airborne droplets, mumps is less contagious
than measles or varicella. Humans are the only reservoir of this infection, which con-
fers lifelong immunity. The global impact of mumps is unknown but is perceived to be
less than that caused by rubella.
Mumps vaccine is highly effective in a single dose when administered after 1 year
of age. Most commonly the vaccine is administered in combination with rubella and
measles vaccines as MMR vaccine, which requires refrigeration and is administered
by injection. Several countries in the Americas, Western Pacific, and Europe include
MMR vaccine among the standard group of vaccines recommended for children.
Mumps meningitis reportedly disappeared in Cuba following increased vaccination of
young children with MMR vaccine. Additional studies are needed to evaluate the im-
pact of mumps (and rubella) in developing countries, as well as the impact of mumps
vaccine, including effects of underimmunization (partial suppression of wild virus).
The potential synergy of a combined campaign against mumps along with measles
and rubella is perhaps the factor most favoring its eradication. Mumps is probably
eradicable with MMR vaccine.
Rubella
Rubella causes mild disease when acquired postnatally, but it can cause severe
birth defects in at least 20%–25% of infants born to women infected during the first
trimester of pregnancy (31 ). It occurs worldwide. Most infections are subclinical, but
these do not appear to play an important role in transmission. Little is known of the
disease’s impact in developing countries, but serologic surveys indicate that most Af-
rican children are immune to the virus by their tenth birthday. There is no animal
reservoir of infection, and this disease is less contagious than rubeola.
The live-virus vaccine is effective in a single dose and is often administered as part
of a triple vaccine against measles, mumps, and rubella (MMR), so that its marginal
cost is extremely small. Use of the vaccine has reduced or interrupted transmisssion
in several countries, including Cuba, Sweden, Finland, and the United States. Immuni-
zation strategies include universal vaccination of children and susceptible women of
childbearing age. The potential for increasing susceptibility in women by underimmu-
nization of children (partial suppression of wild virus) must be avoided. An increasing
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number of countries include MMR vaccine in their routine immunization services. Ru-
bella can be eradicated, and the availability of the MMR combined vaccine has
lowered the marginal costs of rubella eradication. More data regarding rubella’s im-
pact in developing countries are needed. A strategy that does not inadvertently
increase the number of susceptible women should be used.
Taeniasis/Cysticercosis (Pork Tapeworm)
Human beings are the only definitive hosts of Taenia saginata (beef tapeworm) and
Taenia solium (pork tapeworm) (26 ). The beef tapeworm is associated with cattle hus-
bandry; it is the more widespread of the two and is increasing in Europe. Both species
are most prevalent in Latin America, Asia, and Africa. Humans are infected by eating
inadequately cooked, contaminated beef or pork. The eggs of T. solium are also infec-
tive to humans, who may develop a life-threatening dissemination of larvae to cause
cysts in various tissues. Epileptic seizures are a major manifestation when such cysts
occur in the brain. Approximately 50 million persons are infected with both parasites;
some 50,000 die of cysticercosis annually.
Effective means now exist for surveillance to identify foci of transmission of T.
solium and for mass treatment of humans (e.g., praziquantel and niclosamide) to help
eliminate such foci. This parasite causes a substantial economic burden to the pork
industry. T. solium has disappeared gradually from most European countries even
without targeted control measures. Research priorities include development of a
more sensitive diagnostic test for use in pigs and a better way to identify infected
persons. T. solium cysticercosis is potentially eradicable through surveillance and
available interventions, but such feasibility needs to be demonstrated in a sizable geo-
graphic area.
Diseases of which Some Aspect Could Be Eliminated
Hepatitis B
Hepatitis B is a viral disease that is responsible for more than 250,000 deaths per
year worldwide (32 ). High incidences are found in Alaska and other arctic areas, Af-
rica, China, Southeast Asia, and the Amazon. Many infections are asymptomatic.
Hepatitis B is transmitted in early childhood, often perinatally from mother to infant;
sexual and other transmission by direct contact also occur. About 5% of infections
occur in utero. More than two thirds of persons infected in infancy become persistent
carriers of the virus. Deaths result from liver cancer or chronic liver disease, including
cirrhosis.
A vaccine to prevent hepatitis B was introduced in the late 1970s. Three doses are
required, beginning at birth or in early infancy in areas where the disease is highly
endemic. Some countries have begun routine mass vaccinations of infants against
hepatitis B as a part of their Expanded Programme on Immunization. An alternative
approach is to vaccinate only infants of infected mothers who have been identified by
prior screening. At the current cost of U.S. $7.60 per dose of vaccine, hepatitis B could
be eventually eliminated from the United States at a cost of about $120 million per
year, compared with an estimated annual cost of $750 million for treating persons
who contract the disease. Reduction of disease would not begin to be evident for
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about 15 years. It is not possible to eradicate hepatitis B now, but it is technically fea-
sible to eliminate its transmission by universal vaccination programs.
Iodine Deficiency Disorders
More than a billion persons are at risk for this noninfectious condition, which is the
leading preventable cause of intellectual impairment in the world (33 ). The number of
persons affected is unknown, but prevalences of the most severe form, cretinism,
often reach 3%–15% in areas where the disease is highly endemic. Goiter and hypo-
thyroidism are other manifestations of the deficiency. The main risk factor involved is
exclusive or nearly exclusive consumption of locally grown foods in areas where the
soil is deficient in iodine.
Interventions include adding iodine to salt, tea, fish paste, or bread, at a cost of US
$0.02–0.04 per person per year for iodized salt. Iodized oil is available in injectable or
oral forms. Interventions for iodine deficiency can also be combined readily with inter-
ventions for vitamin A and/or iron deficiency. A new assay is available to measure
levels of thyroid hormone in samples of blood from a fingerstick. Methods such as
iodized salt were used to eliminate iodine deficiency disorders more than 40 years ago
in Australia, England, New Zealand, Switzerland, and the United States. Bolivia and
Ecuador have almost eliminated the condition. WHO has endorsed a goal of elimina-
tion of iodine deficiency disorder by the year 2000. There is great need for improved
surveillance and estimates of the prevalence of these disorders and of their economic
impact. Iodine deficiency disorders can be eliminated.
Neonatal Tetanus
WHO estimates that as of 1990 approximately 560,000 deaths caused by tetanus
infections in newborns occurred annually in developing countries, mostly in Asia and
Africa (34 ). Newborns are infected by spores of the bacterium Clostridium tetani
when the umbilical stump is contaminated by unclean instruments or hands used to
cut the cord at birth and/or dressings applied to the area in the first few days of the
infant’s life. The spores are found widely in the environment, where they are associ-
ated with the feces of ungulates. Most infected infants die of the disease.
Neonatal tetanus can be prevented by promoting clean deliveries and by vaccinat-
ing women of childbearing age and children. Based on this strategy, in 1989 WHO
declared the goal of eliminating neonatal tetanus by 1995. As of 1990, only about 58%
of women of childbearing age worldwide (43% in developing countries) had received
the two injections of vaccine required to protect their infants. To achieve better con-
trol, the number of doses of vaccine required to confer protection should be reduced
and surveillance of the disease and monitoring of vaccination coverage should be im-
proved. The reservoir of tetanus spores in the environment is the major barrier to
elimination of neonatal tetanus, which cannot be eradicated. Preventing transmission
of this disease by continuing the interventions mentioned above, however, is possible.
Onchocerciasis (River Blindness)
Onchocerciasis is caused by a parasitic worm, Onchocerca volvulus, which is trans-
mitted to persons by biting blackflies that breed in fast-flowing rivers (25 ). The adult
worms live for up to 15 years in nodules beneath the skin and muscles of infected
persons, where they produce millions of embryos (microfilariae) that invade the skin,
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eyes, and other tissues. Some microfilariae are taken up from the skin by blackflies to
continue the reproductive cycle. About 18 million persons are affected, mostly in Af-
rica (99%), Yemen, and Latin America. Both living and dead microfilariae cause severe
itching in the skin and sometimes blindness after many years. Approximately 340,000
persons have become blind from the disease.
Until the 1980s, the main control measure was to use larvicides to kill immature
blackflies in rivers. This method has been used effectively by the multicountry Oncho-
cerciasis Control Program to reduce the incidence of the disease in part of West Africa
over the past 2 decades, but it is expensive. Since 1987, the drug ivermectin has been
provided by the manufacturer free of charge to control programs for treating persons
with onchocerciasis. This treatment is effective in a single oral dose, administered
once annually; it prevents accumulation of microfilariae in persons at risk. No drug
suitable for mass treatment can kill the adult worms in the host’s body, and onchocer-
ciasis cannot be eradicated without such a means. The blindness, however, can be
eliminated.
Rabies
More than 50,000 persons die of rabies each year, mostly in China and India (35 ).
Humans are infected by saliva introduced into wounds by the bite of a rabid wild or
domestic animal, usually a dog. Canine rabies is endemic throughout most of Asia,
Africa, and Latin America. Rabies also is endemic among some wild animals (e.g.,
foxes, raccoons, skunks, and bats) in North America and Europe. Rabies is almost
always fatal.
Some developed countries have virtually eliminated rabies in humans by mass
vaccination of domestic dogs and destruction of stray dogs. This approach is difficult
to apply in rural areas of most developing countries, where animals may not be pri-
vately owned, destruction may be unacceptable, and such campaigns may be
expensive. Some Latin American countries are conducting successful campaigns in
cities, however. Attempts are being made to control rabies in wildlife by development
of oral vaccines that can be safely distributed in baits. Eradication of rabies is not
feasible, primarily because of the extensive, varied animal reservoirs of the virus and
the inability to eliminate those reservoirs through available technology. It is possible
to eliminate human rabies in urban areas, although the costs and benefits of doing so
should be considered.
Trachoma
Trachoma is a chronic inflammatory disease of the eye caused by repeated infec-
tion with certain types of Chlamydia trachomatis, which often results in blindness
(36 ). Approximately 500 million persons are infected worldwide, some 6–8 million of
whom have become blind. The disease progresses to blindness in about 5%–20% of
the infected population. It is transmitted mainly among children and from them to
women, perhaps during child care. Important risk factors include low socioeconomic
status and inadequate supplies of water.
Effective interventions include mass treatment with tetracycline ointment, which is
effective in the short term. The disease, however, usually returns within 6–12 months
to pretreatment levels in a community. Promotion of increased face-washing and sur-
gery of the scarred eyelids to prevent continued damage to the cornea by turned-in
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lashes are other interventions. There is need for more research into the costs and
benefits of interventions, the epidemiology of various risk factors, and documentation
of previous successes in control of the disease. It appears scientifically feasible to
eliminate blindness caused by trachoma—but not the infection or agent itself— by a
combination of community-based education to promote face washing and targeted
antibiotic treatment.
Yaws and Other Endemic Treponematoses
Each year, approximately 2.5 million persons, mostly children, contract yaws, en-
demic syphilis, or pinta—all closely related infections that are transmitted
nonsexually, mainly by skin-to-skin contact (37 ). These diseases rarely are fatal but
often disfigure or cripple affected persons by invading their skin, bones, and cartilage.
Endemic treponematoses occur in poor rural communities in tropical Africa, Asia, or
Latin America. All three diseases are characterized by a positive serologic test that
cannot be distinguished from the positive test caused by venereal syphilis. For each
person with obvious skin lesions, two or more persons have latent infections.
Mass treatment campaigns conducted during the 1950s and 1960s with injectable
penicillin pushed yaws almost to extinction. Yaws and endemic syphilis have since
resurged, especially in West Africa. Serologic testing, treatment with penicillin, and
improvement in personal hygiene are the main interventions, all of which could be
implemented as a part of primary health care. Similar infections have been seen in a
few nonhuman primates but do not appear to be epidemiologically important. Devel-
opment of tests to reliably distinguish these treponemes and their serologic reactions
would facilitate control efforts. The potential for emergence of penicillin-resistant
strains lends urgency to the need for better control. Eliminating transmission of these
diseases seems feasible.
Diseases that Are Not Eradicable Now
Ascariasis (Roundworm)
Ascariasis, caused by the intestinal parasite Ascaris lumbricoides (large round-
worm), is one of the most common infections of humans, affecting an estimated one
billion persons at any one time (38 ). It affects ≥50% of populations in tropical and
subtropical areas. Its clinical effects include respiratory or abdominal symptoms and
discomfort, with or without associated malnutrition, especially in young children. Po-
tential complications include obstruction of the bile duct by a worm or, more
commonly, intestinal obstruction by a mass of worms. Globally, ascariasis causes an
estimated 20,000 deaths per year. Humans are infected when they ingest soil contami-
nated (by human feces) with eggs of the parasite on their food, fingers, or drink.
An adult ascaris may live up to one and a half years. Humans are the only reservoir,
but the eggs may remain viable in soil for years. Diagnosis requires careful examina-
tion of a fecal sample by a trained microscopist. Control measures include sanitation
and education to promote using latrines, washing hands and food, and avoiding use
of uncomposted human feces as fertilizer; mass chemotherapy; and provision of safe
water for household use. Modern anthelmintics administered in a single dose are safe
and relatively inexpensive and are effective for several months. Ascariasis is not now
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eradicable, but it could be better controlled through mass chemotherapy and hygiene
education of schoolchildren.
Cholera
Cholera, characterized by severe watery diarrhea, dehydration, and high mortality
in untreated cases, is caused by the bacterium Vibrio cholerae 01 (39 ). Many infec-
tions are asymptomatic. Although cholera disappeared from much of the world in the
19th century, the current pandemic of the El Tor cholera biotype has been exacerbated
by larger human populations, faster travel, and greater survival in the environment.
The disease has appeared in more than 100 countries in the past decade and >70,000
cases were reported to WHO in 1990, but the global prevalence of cholera is unknown.
It is associated with unsanitary conditions and may be spread by fecal contamination
of food, water, or hands. No effective immunity develops.
There is no known animal reservoir, but foci of the organism are now known to
persist for years in aquatic environments in the Gulf of Mexico and eastern Australia.
The current vaccine gives only limited protection for several months. Oral rehydration
can reduce mortality rates. Antibiotic drugs may shorten the duration of illness and
stop excretion of the vibrios. Cholera is not now eradicable, although better control is
possible by providing clean water, sanitation, and health education. Priority research
needs are to understand the environmental reservoirs better (e.g., how does the or-
ganism survive? are there other such foci?) and to understand the molecular basis for
differences among strains of V. cholera.
Diphtheria
This disease, caused by infection with Corynebacterium diphtheriae, is charac-
terized by respiratory obstruction and/or myocarditis as a result of a toxin released by
some strains of the bacteria. It is spread by direct contact and airborne droplets (40 ).
Less harmful infections of the skin occur more commonly in developing countries. An
asymptomatic carrier state may follow infection. In the prevaccine era, diphtheria was
a major cause of illness and death in children in urban temperate areas. The global toll
is unknown, but cases reported to WHO declined from 77,000 in 1974 to <24,000 in
1988. It is not known if the nontoxigenic strain of diphtheria induces immunity to in-
fection. Humans are the only reservoir.
The vaccine is an antitoxin, which usually is administered as a part of the DTP or DT
vaccines, in at least three doses administered by injection at 1-month intervals.
Booster doses are also necessary. Widespread use of this vaccine has reduced the
incidence of diphtheria in developed and many developing countries. In the United
States, fewer than five cases were reported annually during the 1980s. No cases were
reported in Sweden for a 24-year period. Recently, DTP vaccine has been used more
widely in developing countries. There has been a recent resurgence of this disease in
Russia. Diphtheria might be eradicable, but its effects in developing countries and the
epidemiologic impact of immunization are not completely understood.
Hookworm Disease
Hookworm infections in humans are usually caused by Ancylostoma duodenale or
Necatur americanus, which together infect an estimated 900 million persons in tropi-
cal and subtropical areas (41 ). Local prevalence rates vary from 10% to 90%; they
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peak in the later teenage years and among young adults. Infections become clinically
important when enough worms are present to cause anemia from loss of blood as a
result of the worms, which live in the intestine. About 60,000 persons die of the infec-
tion annually, but many infections do not cause symptoms. Hookworm is transmitted
when skin comes into contact with moist soil or vegetation that harbors infective lar-
vae hatched from eggs in the feces of an infected person. Adult worms may live 1–5
years. Larvae in soil remain viable for 3–4 weeks. Humans are the only known reser-
voir of this infection.
Preventive measures and treatment are similar to those for ascariasis, except that
wearing shoes also protects against hookworm larvae and administration of iron sup-
plements can reverse the resultant anemia. Sociologic barriers to control include the
association of the disease with poverty, poor personal hygiene and defecation prac-
tices, and use of human feces as fertilizer—all factors that are difficult but not
impossible to change. An attempt to eradicate hookworm in the United States early in
the 20th century failed, and there is little or no political support for another attempt.
Hookworm is not now eradicable.
Leprosy (Hansen’s Disease)
This chronic infectious disease caused by Mycobacterium leprae affects an esti-
mated 11–12 million persons worldwide (42 ). Leprosy is usually nonfatal but may be
severely disfiguring and disabling, and affected persons are often ostracized. Pro-
longed contact with an infected person is required for transmission. Wild infected
armadillos shed the bacteria into the soil and may transmit the disease from animal to
animal.
The introduction of sulfones for chemotherapy in the 1940s was a major break-
through, although many years of therapy were required for cure. Combination therapy
with two to three drugs has had a major impact on the severity of the disease over the
past decade. The new drug regimens are shorter but still require 6–24 months of ther-
apy. Resistance of leprosy bacilli to chemotherapeutic drugs is an increasing problem.
China, Japan, and South Korea have rapidly reduced the incidence and prevalence of
this disease in recent years. India and China established national programs with goals
of halting transmission of leprosy by 2000. In 1991, WHO set the goal of eliminating
leprosy (defined as incidence <1/10,000 population) worldwide by 2000. This disease
is not now eradicable. Impediments include absence of a fast, simple diagnostic test;
persistence of organisms, even in treated persons; cost and side effects of drugs; du-
ration of chemotherapy; patient compliance; and the social stigma associated with the
disease.
Measles
Almost a million persons, mostly infants and young children, die annually from
measles. Especially in Africa, it often leads to death from pneumonia, diarrhea, and
malnutrition (43 ). Measles is highly contagious and spreads by airborne droplets ex-
haled by infected persons up to 2 days before the characteristic rash appears. Persons
who recover are immune to reinfection for life. The successful global campaign to
improve vaccination levels by 1990 reduced the incidence of measles substantially. A
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single injection of vaccine is usually sufficient to confer long-lasting immunity, but to
be effective it must be administered after the infant’s maternal immunity has waned.
Measles vaccine has been used to reduce the incidence of the disease in the United
States, Canada, Cuba, and some European countries, but the disease has not yet been
eliminated from any large country. In 1977, the United States established the goal of
eliminating measles from the country by 1982. It reduced reported cases to <3000 per
year from prevaccine levels of >100 times that number, only to have the disease re-
bound to 25,000 cases in 1990. European and Caribbean countries plan to eliminate
measles by 1995. WHO has established the goal of reducing the global incidence of
measles by 90% by 1995. The ineffectiveness of the vaccine for infants at birth or soon
after and the high degree of contagion of the infection are the principal barriers to
eradication of measles.
Pertussis (Whooping Cough)
This disease, caused by the bacterium Bordetella pertussis, occurs worldwide (44 ).
It primarily affects infants and young children, with peak incidence in the first 2
months of life, and is characterized by a severe, protracted cough. Globally, pertussis
still causes about 40 million cases and 400,000 deaths annually. It is spread from per-
son to person by direct contact and airborne droplets and is highly contagious.
Persons who recover are immune. Humans are the only reservoir of the infection.
Pertussis vaccine is part of the combined Diphtheria-Tetanus-Pertussis vaccine
(DTP), which is administered by injection and requires three to four doses to be effec-
tive. Use of this vaccine has reduced pertussis incidence by more than 99% in the
United States since 1940. The high infectiousness of pertussis, the occurrence of
much of its impact within the first 2 months of life, and the need to administer at least
three doses of vaccine (each dose at 1-month intervals) to achieve adequate protec-
tion are major impediments to control. Better control could result from an improved
vaccine (e.g., fewer doses, greater efficacy, and safety for adults), improved diagnostic
methods, and study of the epidemiology of pertussis in developing countries. If a safe
antigen were available for use in adults, researchers could investigate the possibility
of protecting infants by booster vaccination of pregnant women. Pertussis is not now
eradicable.
Rotaviral Enteritis
Some 80 million episodes of moderate to severe diarrhea and an estimated 870,000
deaths per year are due to rotavirus, which is the most common cause of severe diar-
rhea in children (45 ). It is found in both developed and developing countries. The
virus is spread mainly by the fecal-oral route, but the mode of spread among young
children is uncertain. Some infections in India may originate from cattle. Infection ap-
pears to protect children against subsequent attacks of severe disease.
Improved hygiene, including handwashing, is the main available mode of prevent-
ing spread of the disease. Use of oral rehydrating solution can mitigate clinical effects.
An effective vaccine is not yet available for preventing this infection. Priority research
needs include development of an effective vaccine, studies of the antigenic diversity
of strains of the virus in developing countries, development of an animal model, and
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further investigation of mechanisms of immunity. Rotaviral enteritis is not now eradi-
cable.
Schistosomiasis (Bilharziasis)
Most human infections with this debilitating disease are caused by Schistosoma
mansoni, S. japonicum, or S. hematobium (46 ). All three parasites, except possibly S.
hematobium, have important nonhuman reservoir hosts. About 200 million persons
are affected in Asia, Latin America, and especially Africa. Infection is usually acquired
in childhood, with peak prevalence and intensity among persons 10 to 19 years of age.
Untreated, chronic infection may last 3–4 decades. Persons are infected when they
enter fresh water sources and larval forms of the parasite penetrate the skin. Such
sites are contaminated by egg-bearing feces or urine from infected persons, allowing
the worm to enter snails and multiply before becoming infective to humans. Modern
dams and irrigation projects have often increased the habitat of the snails.
Modern mass chemotherapy has increased the potential for control of this dis-
ease—as demonstrated already in parts of Brazil, China, and Egypt. Single oral doses
of some anthelmintics can decrease worm burdens for ≥1 year, depending on the drug
and parasite species. Health education to reduce contamination of and exposure to
transmission sites and provision of safe water and sanitary facilities are also vital.
Schistosomiasis is not now eradicable, but better control is possible, especially by
mass chemotherapy and hygiene education for schoolchildren.
Tuberculosis
Tuberculosis (TB) infects 8–10 million persons and kills an estimated 2–3 million
annually (47 ). It occurs in all countries but is an especial public health problem in
many developing nations. This bacterial infection is spread from person to person by
respiratory droplets, especially in crowded, poorly ventilated conditions. Recently, its
spread has been facilitated by the concomitant infection of many patients with human
immunodeficiency virus (HIV).
Improved living conditions, case finding, drug treatment, isolation of infectious pa-
tients, and selective chemoprophylaxis reduced TB incidence in many industrialized
countries in the 20th century. Bacille Calmette-Guerín (BCG) vaccine has been used in
some countries to help protect infants and young children from potentially fatal com-
plications of TB. Emergence of strains of Mycobacterium tuberculosis that are
resistant to one or more of the drugs used for treating the disease has complicated
and hampered control programs in the past few decades. In the late 1980s, the United
States declared a goal to eliminate TB in the country by 2010 (defined as an annual
case rate of <1/1,000,000 population). There is need for more accurate, rapid diagnos-
tic tests; shorter and less expensive therapies; better case finding in persons at risk;
and a safer, more effective vaccine. It is not now feasible to eradicate TB.
Yellow Fever
Yellow fever is believed to cause more than 10,000 deaths annually in South Amer-
ica and Africa, but its incidence varies because of sporadic epidemics, in addition to
ongoing endemic transmission of the disease (48 ). It is usually transmitted to humans
by bites of Aedes aegypti mosquitos in urban areas or by bites of other mosquito
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vectors in sylvatic settings. A permanent cycle of the virus is maintained in jungle-
dwelling primates.
An effective vaccine has been available for more than 50 years, although it must be
refrigerated and administered by injection. It is recently being included in Expanded
Programmes of Immunization in some African countries, as recommended by WHO.
Research to improve the current vaccine would be helpful. More aggressive use of the
current vaccine could stop urban yellow fever and reduce epidemics in rural areas.
Because of the sylvatic reservoir of infection, however, yellow fever cannot be eradi-
cated.
Diseases that Are Not Eradicable
Amebiasis
Amebiasis is caused by the protozoan Entamoeba histolytica, a parasite that usu-
ally lives in the large intestine of humans, who are its only reservoir (49 ). Some 500
million persons may be infected worldwide, of whom 38 million may develop serious
complications (e.g., liver abcess and colitis); 40,000–110,000 persons may die annu-
ally. The disease is associated with specific strains of the parasite that have
characteristic enzyme patterns. It is especially prevalent in parts of Latin America, Af-
rica, and Asia. The infection is spread by ingestion of the hardy cysts on food or hands
or in contaminated drinking water. Most infected persons are asymptomatic; some
may excrete cysts for years.
Diagnosis usually requires examination of fecal specimens by a skilled microsco-
pist. Serologic tests and imaging techniques to detect internal abcesses are also used.
Drug therapy can eliminate the parasite in the intestine and other organs, but most
such drugs must be administered for several days. Proper disposal of human feces,
education of persons at risk, and detection and treatment of infected persons are key
interventions. Amebiasis is not now eradicable. Current barriers might be overcome if
an effective, safe drug became available that could be administered to large groups in
a single oral dose without prior testing. Control would also be facilitated if it can be
established that only amoebae from symptomatic persons cause symptomatic dis-
ease in others.
Bartonellosis
This bacterial infection (Bartonella bacilliformis ) is limited to certain mountainous
areas of Peru, Ecuador, and Colombia, where it is transmitted by the bite of an infected
sandfly (50 ). It also can be transmitted by transfusion of blood from an infected per-
son. Infected persons may harbor the bacterium in their blood for many years. The
disease may manifest as severe anemia with fever or as a painful skin eruption accom-
panied by pain in the muscles and joints. The number of persons affected is unknown,
but approximately 40% of cases may be fatal and as many as 5% of populations in
areas where the disease is endemic may harbor asymptomatic infections. Humans are
the only known reservoir of the infection. Persons may remain infective to sandflies
for many years.
The infection is diagnosed by microscopic examination of blood or affected skin or
by culturing blood on special media. Treatment requires administration of high doses
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of antibiotics for at least 7 days. The risk of sandfly bites can be reduced by appropri-
ate insecticides and other protective measures. This infection is not eradicable.
Clonorchiasis
This infection (caused by the parasite Clonorchis sinensis) is endemic in parts of
China, Japan, Korea, and Southeast Asia (51 ). More than 20 million persons are in-
fected in China alone. Persons become infected by eating raw or inadequately cooked
freshwater fish (e.g., carp species or crayfish). In humans, the parasite lives in the bile
ducts, and its eggs are discharged in the feces, sometimes for as many as 30 years.
After the eggs are discharged, the parasite must first enter a snail, then a fish as inter-
mediate host. Infection in humans is often asymptomatic, but it can cause abdominal
pain, gallstones, and cancer of the biliary tract. Pigs, dogs, cats, and rats are also res-
ervoirs of this parasite. Transmission is most frequent, however, in areas where
human feces are used to fertilize fish ponds and where harvested fish are eaten raw.
Diagnosis is made by identifying the eggs in fecal specimens, but the eggs of a
similar parasite (Opisthorchis ) are identical. Serologic testing is also helpful. Drug
treatment for 1–2 days is effective. Preventive measures include proper disposal of
human feces and thorough cooking or freezing of freshwater fish for at least 5 days.
This infection is not eradicable because of the nonhuman reservoir, the many asymp-
tomatic infections of humans, and the fact that some infected persons can shed eggs
for decades. Its prevalence could be reduced, as with that of several other infections,
by promotion of sanitary disposal of human feces.
Enterobiasis (Pinworm)
Enterobiasis is an extremely common parasitic infection, often of young children,
in temperate and tropical countries (52 ). Humans are the only hosts of the infection,
which is caused by pinworm, Enterobius vermicularis. The tiny adult worms live in the
large intestine for ≥90 days. They deposit larvae-containing eggs on or near the anus,
where their presence causes itching. Children are infected by putting fingers that have
been contaminated from scratching into their mouths or by inhaling and then swal-
lowing the eggs, which may become airborne with household dust. The eggs can
remain viable in the environment for approximately 2 weeks. Associated pathology is
unusual, but the parasite may cause chronic appendicitis or invade the female genital
tract.
Diagnosis is made by identifying the microscopic eggs in scrapings or on adhesive
tape that has been pressed to perianal skin. Several anthelmintic drugs are effective
when administered in a singe oral dose, but infected persons, their families, and other
close contacts usually should be treated simultaneously at least twice, at 2-week inter-
vals. It would be nearly impossible to arouse support for the eradication of this
widespread infection, since its clinical effects are usually mild or nonexistent.
American Trypanosomiasis (Chagas’ Disease)
Approximately 15–20 million persons in impoverished rural areas of the Americas
from Mexico to Chile are infected with the parasite Trypanosoma cruzi (53 ). The infec-
tion is transmitted by the bite of a triatomine bug (“kissing bug”) or by blood
transfusion, after which there is a long latent period with few or no symptoms. Mani-
festations may include swelling of the eyelid, followed by fever and enlargement of
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the internal organs. Sudden death due to acute cardiac problems can occur in infected
young adults. More than 150 species of domestic and wild animals are hosts of this
parasite, of which there are many strains. Many epidemiologically important species
of the insect vector live in thatched roofs, cracks in walls, and other dark places.
Housing improvements to reduce suitable habitat for the insect vectors and use of
residual insecticides are the main bases for preventive interventions in national con-
trol programs. Diagnosis, whether by blood smear or serology, and treatment are
difficult. Improved diagnosis, methods for screening blood, and treatment are needed.
Chagas’ disease is not eradicable at present.
Varicella (Chickenpox) and Zoster
Varicella-zoster virus causes two diseases: varicella, which mainly affects children
and causes generalized rash and fever; and zoster, which produces a painful localized
rash in adults when latent infection from a prior attack of varicella is reactivated (54 ).
The virus is transmitted by the airborne route from sources in the respiratory tract and
skin. Varicella is highly contagious, comparable with measles. Humans are the only
reservoir of infection, and most who recover are immune for life. The global toll is
unknown, but approximately three million cases of varicella and 300,000 cases of zos-
ter occur annually in the United States alone, including about 100 reported fatal cases.
Varicella appears not to spread as much in tropical countries as in the United States.
A live attenuated vaccine is expected to be licensed in the United States soon, but
it is not as effective as other common live-virus vaccines. Moreover, the durability of
such induced immunity and its potential effect on the incidence of zoster are un-
known. Antiviral therapy with acyclovir can accelerate recovery if it is administered
early in the course of the disease. Immune globulin is an effective prophylactic if ad-
ministered soon after exposure to the virus. The main barrier to eradication of this
disease is the ability of the virus to reactivate from latency to produce zoster, which is
about 25% as infectious as varicella. This infection is not eradicable.
THE FUTURE
The concept and practice of disease eradication are now accepted as useful, re-
spected tools of international public health, to be employed with scientific discretion.
The likely achievement of the next two declared targets for global eradication, dracun-
culiasis by 1995 and poliomyelitis by 2000, together with the precedent already
established by the eradication of smallpox in 1977 (1 year later than the target date),
should ensure the survival and application of the principle of eradication (Table 2).* By
the time dracunculiasis and poliomyelitis are expected to have been eradicated, in-
terim targets for measles (Table 4) should have been attained and progress should
have been made toward the control of other potential targets for eradication that have
been identified by the ITFDE (e.g., mumps, rubella, cyticercosis, and lymphatic filari-
asis). Thomas Jefferson’s “catalogue of evils” may be steadily diminished with these
attainments and with advances in tools for controlling other potential targets such as
*The full text of the World Health Assembly resolutions regarding disease eradication is avail-
able on request to the World Health Organization.
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onchocerciasis (or Haemophilus influenzae b, for which conjugate vaccines have been
licensed).
If the epidemiologic benefits of eradication are not incentive enough, the fiscal re-
wards may help ensure the concept’s acceptability. The United States alone has been
recovering its total investment of about $30 million in the global Smallpox Eradication
Program every 3–4 months since the early 1970s. Since smallpox was eradicated in
1977, that total investment has been returned to the United States every 26 days.
Based on the current rate of progress towards eradication of poliomyelitis, WHO pre-
dicts that campaign will “produce [global] savings of half a billion dollars by the year
2000, increasing to U.S. $3 billion annually by the year 2015.”
The main obstacle to the concept’s current acceptance is that if the concept of eradi-
cation is invoked against inappropriate or unattainable targets, it can again be brought
into disrepute. The declared targets of “elimination” of neonatal tetanus by 1995 and
of leprosy by 2000 are potential examples of such dangers. Care should be taken to
reserve use of the terms “eradication” and “elimination” only for carefully chosen
diseases that have a high likelihood of being eradicated.
Continued advocacy is required to maintain appropriate consideration of the issues
considered and suggestions made by the ITFDE. The Task Force for Child Survival and
Development, which includes several key members of the ITFDE, will review updates
of this topic annually. If new information or the appearance of new control measures,
for example, suggest the need for it, a group may be reconvened to consider other
diseases in depth (e.g., H. influenzae b) or reconsider diseases that were discussed by
the ITFDE. In the interim, the most urgent task for promoting the concept of disease
eradication is to ensure the successful eradication of dracunculiasis by 1995 and of
poliomyelitis by 2000.
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1990 Poliomyelitis elimination in Americas [achieved in 1991]
1991 Dracunculiasis elimination in Pakistan [achieved in 1993]
1995 Dracunculiasis eradication
Poliomyelitis elimination in Europe, Western Pacific
Measles elimination in English-speaking Caribbean
Neonatal tetanus elimination
2000 Poliomyelitis eradication
Measles elimination in Europe
Leprosy elimination (defined as <1 case/10,000 population)
2007 Elimination of onchocerciasis in the Americas
TABLE 4. Diseases targeted for eradication/elimination
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APPENDIX 1. Diseases screened for potential eradicability by the International Task Force for Disease Eradication
Disease/condition Extent of problem
Epidemiologic
vulnerability Intervention(s) available Political will Comment
Actinomycosis Infrequent;
worldwide
Found in normal flora of
oral cavity
Surgery, prolonged
chemotherapy
None —
Acquired
immunodeficiency
syndrome
Spreading
worldwide; 200,000
deaths/year; 6–8
million infected
Sexual transmission; no
natural immunity;
difficult diagnosis
Health education,
condoms; mitigate
infection with
azidothymidine (AZT)
High —
Angiostrongyliasis Infrequent; Pacific
islands, Cuba,
E. Africa
Reservoir in snails,
slugs, rats
Rat control, cook
seafoods
None —
Anisakiasis Infrequent; Asia, N.
Europe, Latin
America
Wide reservoir in marine
fish and squid; difficult
diagnosis
Avoid eating
inadequately cooked
marine fish
None —
Anthrax Sporadic,
occasionally
epidemic;
worldwide,
endemic in parts of
Asia, Africa
Viable spores in soil for
years, also on animal
hides; zoonosis
Immunization, antibiotic
treatment, disinfection
Low —
Arenaviral hemorrhagic
fever
Bolivia, Argentina;
300–600 cases
reported/year
Wild rodent reservoir; no
specific treatment or
vaccine
Rodent control; isolation
of patient
None —
Arboviral encephalitis
(eastern equine
encephalitis (EEE), western
equine encephalitis,
Japanese encephalitis
(JE), St. Louis encephalitis)
(also fever)
N. America, parts of
Asia (JE)
Reservoirs unknown or
widespread in animals
Mosquito control,
vaccine for JE, EEE
Low; epidemic
economic
burden
—
*
*To determine which diseases could qualify for further consideration by the International Task Force for Disease Eradication (ITFDE), these
draft criteria were used to screen 94 infectious diseases listed in the 14th edition of Control of Communicable Diseases in Man (Benenson
AS, ed. Washington, DC; American Public Health Association, 1985). The preliminary proposed disposition is indicated in the last column
of the table under “Comment;” a line (—) means the disease was deemed unsuitable for further consideration by the ITFDE. Note that
diseases discussed in the text are not listed here.
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APPENDIX 1. Diseases screened for potential eradicability by the International Task Force for Disease Eradication
Disease/condition Extent of problem
Epidemiologic
vulnerability Intervention(s) available Political will Comment
Aspergillosis Worldwide;
uncommon
Reservoir in decaying
vegetation; spread by
inhalation of airborne
spores
Treatment difficult None —
Babesiosis N. America, Europe,
rare
Rodent or cattle reservoir Rodent, tick control;
chemotherapy
Low —
Balantidiasis Worldwide; low
incidence
Reservoir in swine,
feces, possibly others;
resistant to water
chlorination
Sanitation, chemotherapy None —
Blastomycosis Uncommon; Asia,
Africa, N. America
Reservoir probably in
soil; inhaled
Chemotherapy difficult None —
Brucellosis Worldwide; 200
cases/ year reported
in USA
Reservoir in domestic
and wild animals;
serologic diagnosis
Education, milk
pasteurization;
chemotherapy
Low —
Candidiasis Worldwide Part of normal human
flora
Treatment difficult None —
Capillariasis Philippines;
1,500 cases since
1963; 10%
case-fatality rate
Possible reservoir in
aquatic birds; life cycle
uncertain
Avoidance of raw fish None —
Chancroid Worldwide,
especially tropics
Sexual transmission; no
immunity; difficult
diagnosis
Oral antibiotic treatment
for 7–10 days
None —
Cat-scratch disease Worldwide;
uncommon, usually
self-limited
Reservoir in cats; no
specific treatment
None None —
Chlamydial infections
(genital)
Worldwide;
common; important
cause of infertility
Sexual transmission;
most patients
asymptomatic; no
immunity; diagnosis
difficult
Health education;
antibiotic therapy
Low —
Chromomycosis Worldwide; sporadic Reservoir in wood, soil,
decaying vegetation
Treatment very difficult None —
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APPENDIX 1. Diseases screened for potential eradicability by the International Task Force for Disease Eradication
Disease/condition Extent of problem
Epidemiologic
vulnerability Intervention(s) available Political will Comment
Coccidioidomycosis Arid parts of
Americas
Reservoir in soil;
inhalation; most infected
persons acquire
immunity; occupational
exposure; diagnosis by
culture and skin test
Outdoor dust control;
treatment difficult
Low —
Cryptococcosis Sporadic;
worldwide,
increased incidence
related to AIDS
Reservoir in soil, pigeon
droppings; difficult
diagnosis
Disinfection (chemical);
difficult treatment
None —
Cryptosporidiosis Probably worldwide Reservoir in cattle, other
domestic and wild
animals; fecal-oral
transmission; diagnosis
by fecal smear or
intestinal biopsy
Personal hygiene None —
Cytomegalovirus disease Common;
worldwide; severe
infection in some
infants; some
morbidity in
infected adults;
increased incidence
related to AIDS
Humans only known
reservoir; many
inapparent infections;
direct contact with
infected secretions; viral
shedding in urine or
saliva for years;
diagnosis by viral
isolation, serology
Sanitation, hygiene; no
vaccine or treatment
None —
Dengue fever Tropical Asia, W.
Africa, Caribbean
and Central
America; periodic
epidemics with
fatalities
Possible monkey
reservoir; homologous
immunity; dengue
hemorrhagic fever
associated with Aedes
aegypti vector; four
serotypes; diagnosis by
serology, culture
Mosquito control Low —
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APPENDIX 1. Diseases screened for potential eradicability by the International Task Force for Disease Eradication
Disease/condition Extent of problem
Epidemiologic
vulnerability Intervention(s) available Political will Comment
Campylobacter diarrhea Causes 5%–14% of
all diarrhea
worldwide; some
traveler’s diarrhea
Reservoir in many
animals, including pets;
diagnosis by stool
isolation
Sanitation; oral
rehydration, some
antibiotics
Low —
Diphyllobothriasis N. America, Europe From inadequately
cooked freshwater fish;
reservoir also in dogs
and bears; diagnosis by
fecal examination
Praziquantel treatment None —
Ebola-Marburg virus Some parts of
Africa; often fatal
Unknown reservoirs in
African animals;
person-to-person
transmission
Disinfection; quarantine None —
Echinococcosis Asia, America,
Africa in association
with herd dogs
Diagnosis by
microscopy, x-ray,
serology; contaminated
hands, food, water; wide
reservoir in domestic
and wild animals
Hygiene, surgery;
destruction or mass
chemotherapy of dogs
None —
Fascioliasis Cattle-raising areas
of Asia, Americas,
Europe
Reservoir in cattle, other
large herbivores; from
uncooked watercress;
diagnosis by fecal exam
Praziquantel
chemotherapy, education
None —
Fasciolopsiasis Southeast Asia Reservoir in pigs,
humans, dogs; from
uncooked plants;
diagnosis by microscopy
of feces
Sanitation, education;
praziquantel
chemotherapy
None —
Giardiasis Worldwide cause of
chronic diarrhea
Reservoir in beavers;
large proportion of
infections asymptomatic;
diagnosis by stool smear
Sanitation, hygiene,
water supply;
chemotherapy
None —
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Disease/condition Extent of problem
Epidemiologic
vulnerability Intervention(s) available Political will Comment
Gonorrhea Common
worldwide; major
cause of infertility,
abdominal
infections (acute)
No nonhuman reservoir;
chronic carrier state
possible; sexually
transmitted; no natural
immunity; diagnosis by
microscopy
Health education;
condoms; chemotherapy
limited by wide
resistance to penicillin
Low —
Herpes simplex Both types common
worldwide
Humans only reservoir;
direct contact, sexual
transmission; long
latency; microscopic,
serologic diagnosis
Condoms; health
education; acyclovir
orally or topically
Low —
Histoplasmosis Almost worldwide;
common focal
infections, clinical
disease uncommon
Reservoir in dust/soil
associated with chickens,
bats and starlings; not
transmitted person to
person; diagnosis by
culture, skin test, or
microscopy
Disinfection;
chemotherapy difficult
None —
Hymenolepiasis Cosmopolitan;
uncommon cause
of disease
Possible reservoir in
mice; infections persist
for years; many
asymptomatic infections;
diagnosis by stool smear
Hygiene and sanitation;
chemotherapy
None —
Influenza Worldwide; major
cause of morbidity
and mortality;
epidemic potential
Animal reservoir
suspected; highly
infectious by respiratory
route; numerous
serotypes, shifting;
type-specific immunity
Partially effective
vaccine;
chemoprophylaxis for
type A
Moderate —
Lassa Fever West and Central
Africa; exportation
to Europe, N.
America; fatal in
epidemics
Wild rodent reservoir;
natural immunity after
recovery; diagnosis by
isolation, dangerous
Rodent control;
quarantine; disinfection;
plasma and ribavirin
Low —
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Disease/condition Extent of problem
Epidemiologic
vulnerability Intervention(s) available Political will Comment
Legionellosis Nearly worldwide
cause of acute
pneumonia, fever;
sometimes fatal
Reservoir in water
systems, possibly soil;
no person-to-person
transmission; diagnosis
by isolation or serology
Disinfection of water
systems; antibiotic
treatment
None —
Leishmaniasis (cutaneous,
visceral)
Extensive sporadic
infection in Old and
New World;
estimated 12
million cases; over
400,000 new
cases/year; visceral
form sometimes
fatal
Extensive wild and
domestic animal
reservoirs; multiple
strains of parasite;
immunity after healing;
diagnosis by
microscopy, serology, or
biopsy
Insecticide control of
sandfly; destroy animal
reservoirs;
chemotherapy difficult
Low —
Leptospirosis Worldwide
zoonosis; low
fatality rate; hazard
in occupations with
animal contact
Extensive reservoirs in
wild and domestic
animals; many
serotypes; diagnosis by
serology or isolation
Rodent control; boots
and gloves; avoidance of
contaminated water;
limited immunization;
weekly
chemoprophylaxis
None —
Listeriosis Sporadic,
uncommon
infection; rarely fatal
Reservoir in infected
human carriers,
domestic and wild
animals; diagnosis very
difficult
Antibiotic treatment None —
Loiasis West and Central
Africa; highly
endemic in some
villages
Humans only reservoir;
microfilariae in humans
up to 17 years; no known
immunity; diagnosis by
microscopy of blood
Vector control of fly; fly
repellents;
chemoprophylaxis;
treatment difficult
(diethylcarbamazine);
ivermectin a possibility
None —
Lyme disease USA, Europe,
Australia
Reservoir in ticks, wild
deer, rodents; clinical
diagnosis, serology
Vector control; palliative
treatment
None —
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Disease/condition Extent of problem
Epidemiologic
vulnerability Intervention(s) available Political will Comment
Lymphocytic
choriomeningitis
Uncommon,
localized infection
Mice, hamster reservoir;
asymptomatic infections;
diagnosis by viral
isolation, serology
Sanitation and hygiene None —
Lymphogranuloma
venereum
Worldwide,
especially tropical,
subtropical
Humans only reservoir;
sexually transmitted,
often asymptomatic,
very chronic; diagnosis
by microscopy, serology
Condoms; 2 weeks of
oral antibiotics
None —
Malaria Mainly tropical;
1–2 million
deaths/year
Humans main reservoir;
relapses, asymptomatic
infections; multiple
strains; diagnosis by
microscopy
Chemotherapy
(resistance); vector
control (resistance);
chemoprophylaxis
(resistance)
High Legacy
of failed
campaign
Melioidosis Asia, Africa,
Americas;
uncommon
Reservoir in some soil
and water; various
animals; often
asymptomatic; relapses;
diagnosis by isolation,
serology
Chemotherapy None —
Meningococcal meningitis
(Neisseria meningitidis)
Widespread;
temperate and
tropical; epidemic
tendency, especially
in hot, dry regions
(Sahel); often fatal
Humans only reservoir;
asymptomatic carriers;
several serogroups;
microscopic diagnosis
Vaccines against some
serotypes; respiratory
isolation; chemotherapy,
chemoprophylaxis (some
antibiotic resistance)
Low —
Haemophilus meningitis Common in USA;
associated with
other clinical
involvement; often
fatal; worldwide
Humans only reservoir;
diagnosis by isolation or
serology
Antibiotic treatment and
prophylaxis; vaccine
against type B
Low —
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Infectious mononucleosis
(Epstein-Barr virus [EBV])
Common,
worldwide; usually
mild; same agent
(EBV) associated
with Burkitt’s
lymphoma,
nasopharyngeal
cancer
Humans only reservoir;
spread by saliva;
convalescent immunity;
difficult clinical
differential diagnosis;
laboratory tests required
Disinfection; reduce
malaria to reduce
incidence of Burkitt’s
lymphoma
Low (vaccine
would elevate)
—
Nocardiosis Worldwide;
occasional, chronic
Reservoir in soil;
transmitted by
inhalation; diagnosis by
microscopy
Some patients respond
to antibiotic therapy
None —
Paragonimiasis Extensive in Asia,
also parts of Africa,
Latin America;
chronic effects in
lung
Reservoirs in domestic
and wild carnivores; no
immunity; diagnosis by
stool examination, chest
x-ray
Avoidance of
inadequately cooked
crabs; sanitation
None —
Pediculosis (body lice) Worldwide, not fatal Humans only reservoir;
spread by direct contact
(including sexual)
Health education,
hygiene; disinfection of
clothing, homes; lotion
or powders
None —
Plague Focal but
worldwide
distribution in wild
rodents; high
fatality rate;
sporadic in western
USA
Extensive wild rodent
reservoir; pulmonary
form spreads human to
human; fleas infective
for months; microscopic
diagnosis
Wild rodent and flea
control; killed bacterial
vaccine; quarantine;
antibiotic treatment
Moderate–
high
—
Pneumonococcal
pneumonia
Worldwide; often
fatal in extremely
old or young
persons or
alcoholics
Humans only reservoir;
many asymptomatic
carriers; diagnosis by
microscopy
Polyvalent vaccine;
antibiotic therapy
Low —
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Psittacosis Worldwide;
sporadic human
cases
Apparently healthy
carriers in birds;
infection by inhalation;
serologic diagnosis
Destruction of infected
birds; public education;
weeks of antibiotic
therapy
None —
Q Fever Worldwide;
epidemics rarely
fatal
Extensive reservoir in
cattle, sheep, goats;
serologic diagnosis
Vaccine; health
education; disinfection;
antibiotics
None —
Relapsing fever Asia, Africa,
Americas; endemic
fatality rates may
be as high as 50%
Epidemic if borne by lice,
endemic if by ticks;
tick-borne reservoir in
wild rodents and ticks;
infected ticks can live for
years; limited immunity;
diagnosis by darkfield
microscopy
Personal and
environmental vector
control; tetracycline
treatment
Low —
Tick-borne rickettsioses
(Rocky Mountain spotted
fever)
Americas or other,
case-fatality rate up
to 20%
Reservoir in ticks, dogs,
rodents; diagnosis
difficult, by serology
Health education, tick
control, antibiotic therapy
Low —
Salmonellosis Worldwide, cause
of diarrhea and
sometimes severe
infections; common
Wide reservoir in wild
and domestic animals,
especially raw dairy
products; numerous
serotypes; carrier state
for months
Thorough cooking of
food; education;
antibiotic therapy
None —
Scabies Widespread cause
of intense skin
infection;
associated with
poverty
Humans only reservoir,
transmission by
skin-to-skin contact or
via clothing
Education, topical
treatment, isolation
None —
Shigellosis Worldwide;
common cause of
severe dysentery
and death,
especially in
children
Humans are main
reservoir, also in primate
colonies; asymptomatic
carriers; several
serotypes;   diagnosis by
microscope, culture
No commercial vaccine;
water supply, health
education, hygiene and
sanitation; oral
rehydration, antibiotics
(resistance occurs)
None —
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Strongyloidiasis Widespread in
tropics and some
temperate areas;
autoinfection
possible, potentially
fatal
Possible reservoir in
dogs as well as humans;
larvae actively penetrate
skin from fecally
contaminated soil;
duration of
communicability up to
35 years; microscopic
diagnosis
Health education,
sanitation,
chemotherapy, shoes
Low —
Syphilis (veneral,
congenital)
Widespread,
especially urban;
≥5% prevalence in
pregnant women;
congenital
infections severe,
fatal, or chronic
Humans only reservoir;
diagnosis difficult;
serology; sexual
transmission; partial
immunity; relapses
Single-dose penicillin
treatment, condoms;
education; finger-stick
serology, case-finding
and treatment
Low
Toxocariasis (visceral
larval migrans)
Chronic disease of
children worldwide;
not common
Reservoir in dogs and
cats; ingestion of soil
contaminated by their
feces; eggs viable in soil
for months; diagnosis
very difficult
Sanitation and hygiene;
education of pet owners;
chemotherapy poor
None —
Toxoplasmosis Worldwide;
common infection;
potential fatal
Wide reservoir in
rodents, cats, swine,
cattle; transmission to
humans transplacental,
via raw meat, or by
ingestion of cat feces;
recovered patients are
immune
Sanitation and hygiene;
education of pet owners;
proper cooking of meat;
chemotherapy
None —
Trench fever Endemic in parts of
Europe, Africa,
Latin America
Associated with body
louse, no other reservoir;
diagnosis difficult
Delousing; antibiotic
therapy
None —
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Trichinosis Worldwide
endemic, sporadic
occurrences,
potentially fatal
Reservoir in mice, rats,
dogs, wild animals,;
associated with eating
poorly cooked pork, wild
animal meat
Proper cooking practices,
freezing of meat
None —
Trichomoniasis Prevalent
worldwide, not fatal
Humans only reservoir;
sexual transmission;
often asymptomatic;
diagnosis by microscopy
Health education,
condoms; chemotherapy
None —
Trichuriasis Worldwide,
especially in
tropics, usually
asymptomatic
Humans only reservoir;
microscopic diagnosis
Sanitation and hygiene;
chemotherapy
None —
African trypanosomiasis Only in tropical
Africa; estimated
25,000 cases and
20,000 deaths per
year; major
problem for
domestic livestock
Reservoir in wild game
for one of the two types;
no immunity; diagnosis
by microscopic exam of
blood or spinal fluid;
serologic diagnosis
improved
Chemotherapy
improved; brush clearing
for vector control; locally
made tsetse traps;
residual insecticides
Low–
moderate
—
Tularemia N. America, Europe,
USSR, Japan;
contact with wild
animals
Extensive reservoir in
wild animals;
transmission by direct
contact, inhalation, or
tick bite; immunity;
diagnosis by serology or
culture
Gloves; live vaccine,
antibiotic therapy,
education
None —
Typhoid fever Worldwide; fatality
rate up to 10%,
25,000 deaths/year
Human asymptomatic
carrier state;
drug-resistant strains;
diagnosis by blood
culture
Hygiene, water,
sanitation; antibiotic
therapy; partly effective
vaccine
None —
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Epidemic louse-borne
typhus
Mountainous cooler
regions of Latin
America, Africa,
Asia; case-fatality
rate 10%–40%
Zoonosis of flying
squirrels in USA;
asymptomatic cases;
relapses after years;
difficult serologic
diagnosis
Chemical delousing,
personal hygiene;
immunization, antibiotic
therapy
None —
Murine typhus Worldwide; milder
than louse-borne
typhus; in
association with
mice
Reservoir in rats; other
wild or domestic animals
may be infected
Rat, mouse control;
insecticides against flea
vectors, antibiotics
None —
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